Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: LaserSight

This article was originally published in The Gray Sheet

Executive Summary

LaserSight: Acquires worldwide distribution rights to the Ruiz disposable microkeratome, an instrument used to create the corneal flap in laser in situ keratomileusis (LASIK) procedures, the St. Louis firm says. The company expects to begin international sales "late this year or early next year" at a price of approximately $7,500; a disposable component used with the device is priced at $125. A 510(k) will be submitted to FDA in the next few weeks for the device. Under the terms of the deal, LaserSight paid $400,000 in cash and supplied one LaserScan LSX scanning excimer laser to the instrument's inventors, Luis Antonio Ruiz, MD, and Sergio Lenchig of Bogota, Colombia; two additional payments of $150,000 each will be made six and 12 months after the initial shipment date...

You may also be interested in...



Chloroquine ‘Approval’ For COVID-19 And The US FDA’s New Reality

Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.

Biopharma, Payers Seek National Guidelines For Prescribing Potential COVID-19 Drugs

Guidelines for health care providers could help prevent shortages as demand for possible treatments surge, groups say. Stakeholders also argue “Buy America” executive order would hamper drug access.

Becton Dickinson, BioMedomics Collaborate On Rapid Serology COVID-19 Test

BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.

UsernamePublicRestriction

Register

MT008852

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel